Skip to content
Friday 14 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,772.67
-0.56%
DAX
26,299.74
0.00%
CAC 40
8,650.56
0.00%
STOXX 50
6,545.47
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Saturday 03 April 2021 11:31 am

UK reports seven blood clot deaths after Astrazeneca vaccine

By: Poppy Wood

Add as a preferred source on Google

Seven people in the UK have died from blood clots after taking Astrazeneca’s Covid vaccine, Britain’s medicines regulator has confirmed.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it received reports of 30 unusual blood clotting events among patients who have received the Astrazeneca jab, of which seven have died.

It is still unclear whether there is a causal link between the coronavirus vaccine made by the Anglo-Swedish firm and an increased risk of blood clots.

However, the MHRA insisted that the benefits of the jab continue to outweigh any potential risks.

Downing Street said it would keep reviewing the evidence but that its advice and vaccination strategy remained unchanged. “We remain absolutely confident in the vaccine,” a Number 10 spokesperson said.

Earlier this week the European Medicines Agency (EMA) said a causal link was “not proven, but is possible”.

The EMA’s refusal to draw a definitive conclusion on potential risks associated with the vaccine has seen several European countries temporarily ban the jab.

Read more

Sweeping job cuts at GSK to fund £400m Cambridge campus

Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.

France, Sweden, Finland, Canada and Germany have all recommended that young people, who have a heightened risk of blood clots, should not take the Astrazeneca vaccine.

The Netherlands has limited the vaccine to those aged 60 or older, pending further guidance from European regulators. 

Germany has restricted the use of the vaccine for under-60s, despite the country lagging far behind Europe in its immunisation programme.

Just 12.9 per cent of adults in the country have received their first dose of a Covid vaccine, according to the European Centre for Disease Prevention and Control. In comparison, more than 60 per cent of adults in the UK have received at least a first dose of the jab.

Meanwhile, Norway and Denmark have both suspended the Astrazeneca vaccine altogether, despite it receiving the green light for continued use by the EMA.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • AstraZeneca
  • Coronavirus
  • Vaccine

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • Grandparents fund university degrees to avoid inheritance tax net

  • Five-star Mayfair hotel hit with HMRC winding-up petition

More from Morning Wire

  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Alkermes plc Reports Second Quarter 2026 Financial Results

    Business Wire
  • Clinigen Appoints Greg Skalicky as Chief Executive Officer

    Business Wire
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook